Infectious Disease Specialist talks Delta variant, Alzheimer’s new drug & more

Bob Sirott

FILE – In this Aug. 14, 2018 file photo, a doctor looks at a PET brain scan at the Banner Alzheimers Institute in Phoenix. Two experimental drugs failed to prevent or slow mental decline in a study of people who are virtually destined to develop Alzheimer’s disease at a relatively young age because of rare gene flaws. The results announced Monday, Feb. 10, 2020, are another disappointment for the approach that scientists have focused on for many years — trying to remove a harmful protein that builds up in the brains of people with the disease. (AP Photo/Matt York, File)

The U.S. Food and Drug Administration approved Aduhelm for the treatment of Alzheimer’s. Researchers evaluated Aduhelm’s efficacy in three separate studies representing a total of 3,482 patients. It is the first approved treatment to attack the disease process of Alzheimer’s instead of just addressing dementia symptoms.

Dr. Aileen Marty, Infectious Disease Specialist & Professor at Florida International University joined Bob Sirott to talk about the new drug and its mixed reviews and concerns about the data. In addition, she shares insight on the Delta variant that scientists believe is more transmissible or can cause more severe disease.

Copyright 2021 Nexstar Media Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Bob Sirott
Weekdays 5-9am BobSirott

Bob Sirott's acclaimed broadcasting career has spanned nearly five decades and has included stints at WMAQ, WBBM-FM, WLS, WGN and various television stations. (Click for more.)

Popular